The GATA-3–dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas
Abstract
Abstract The transcription factor GATA-binding protein 3 (GATA-3) and the transcriptional program it regulates have emerged as oncogenic drivers across diverse T-cell lymphomas (TCLs), many of which are resistant to conventional chemotherapeutic agents and characterized by recurrent losses of key tumor suppressor genes, including TP53 and PTEN, both of which are clients of the nuclear export protein XPO1. Here, we demonstrated that XPO1 is highly expressed by malignant T cells expressing GATA-3 and by lymphoma-associated macrophages (LAMs) within their tumor microenvironment (TME). Using complementary genetically engineered mouse models, we demonstrated that TP53- and/or phosphate and tensin homolog (PTEN)-deficient TCLs, and LAMs within their TME, are sensitive to the selective exportin-1 (XPO1) antagonist selinexor. In an effort to identify TP53- and PTEN-independent mechanisms, we used complementary and orthogonal approaches to investigate the role of eIF4E and XPO1-dependent messenger RNA nuclear export in these TCLs. We identified a novel role for eIF4E/XPO1 in exporting GATA-3 and GATA-3–dependent transcripts from the nucleus in TCLs, and in the export of therapeutically relevant transcripts, including colony-stimulating factor-1 receptor, from LAMs. Therefore, XPO1 antagonism, by impairing oncogenic transcriptional programs in TCLs and depleting LAMs from their TME, is a novel approach to target 2 independent dependencies in a group of therapeutically challenging TCLs.
Article Details
Authors (19)
Nermin Kady
University of Michigan, Ann Arbor, Michigan, United States
Suhaib Abdelrahman
University of Michigan, Ann Arbor, Michigan, United States
Ahmar M. Rauf
1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Alyssa Burgess
Jonathan Weiss
1Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany
Hirushi Gunasekara
Neal Ramseier
1University of Illinois Chicago, Chemistry, Chicago, United States
Ira P. Maine
1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Alejandro Zevallos-Morales
Vanessa Perez-Silos
Ashley Wolfe
1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Alexandra C. Hristov
5Department of Pathology, University of Michigan, Ann Arbor, MI
Noah A. Brown
5Department of Pathology, University of Michigan, Ann Arbor, MI
Kedar Inamdar
3Henry Ford Hospital, Depart of Pathology, Detroit, United States
Maria Sverdlov
Ying S. Hu
Department of Chemistry, University of Illinois Chicago, 845 W Taylor Street, Chicago, Illinois 60607, United States
Carlos Murga-Zamalloa
Chenguang Wang
Ryan A. Wilcox
23Division of Hematology/Oncology, University of Michigan Cancer Center, Ann Arbor, MI